Figure 1. Antigen specificity is retained after conjugation to IRDye800. Three 96 well black plates (bevacizumab shown) were coated in lanes 1–6 with recombinant VEGF, EGFR and IL-6R. Lanes 1–3 were incubated for one hour with varying concentrations of labeled antibody. For control purposes, wells 4–6 were first blocked with purified, unlabeled antibody and then incubated with the same concentrations of labeled antibody (A). The wells were imaged and well intensities quantified with the Pearl impulse imager. Nonlinear regression curves depicting preservation of antigen specificity after IRDye800 labeling were generated using GraphPad Software (B–D).